Subject to the difference of one’s opinion....
The objective of these trials was to compare the efficacy of “SIRT with Y-90 resin microspheres” versus the current standard of care applied now by the use of “sorafenib .“ The results clearly define some of the benefits and the capabilities when used in combating the devastating effects of liver cancer in certain patient cases, I personally don’t believe the trails left a sense of iffy !... in knowing this the job now should be go with what we have and find out what else we can get it can do!
As Prof Valérie Vilgrain, did say it deserved further evaluation.
Ann: Trading Halt, page-64
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.025(15.6%) |
Mkt cap ! $78.52M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 17.5¢ | $392.2K | 2.150M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 871626 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 318889 | 9 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |